Trial Profile
The Phase II of Nimotuzumab in Combination With Radiotherapy for Esophageal Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Mar 2022
Price :
$35
*
At a glance
- Drugs Nimotuzumab (Primary)
- Indications Oesophageal cancer
- Focus Adverse reactions
- Sponsors Biotech Pharmaceutical
- 03 Nov 2015 New trial record